$NURO
NeuroMetrix, Inc.

2014 Q1 Form 10-K Financial Statement

#000114420414011172 Filed on February 24, 2014

View on sec.gov

Income Statement

Concept 2014 Q1 2013 2012 Q4
Revenue $1.332M $5.279M $1.520M
YoY Change -4.89% -30.32% -35.59%
Cost Of Revenue $615.1K $2.194M $680.0K
YoY Change 7.95% -38.86% -43.33%
Gross Profit $716.5K $3.085M $850.0K
YoY Change -13.85% -22.62% -26.72%
Gross Profit Margin 53.81% 58.43% 55.92%
Selling, General & Admin $1.593M $7.005M $2.160M
YoY Change -20.88% -33.05% -21.45%
% of Gross Profit 222.34% 227.11% 254.12%
Research & Development $863.7K $3.438M $570.0K
YoY Change -19.54% -3.03% -31.33%
% of Gross Profit 120.55% 111.47% 67.06%
Depreciation & Amortization $30.00K $150.7K $40.00K
YoY Change -25.0% -37.01% -50.0%
% of Gross Profit 4.19% 4.88% 4.71%
Operating Expenses $2.457M $10.44M $2.720M
YoY Change -20.41% -25.45% -24.02%
Operating Profit -$1.740M -$7.359M -$1.870M
YoY Change -22.83% -26.57% -22.73%
Interest Expense $520.0K -$280.0K $0.00
YoY Change -2900.0%
% of Operating Profit
Other Income/Expense, Net -$290.0K
YoY Change
Pretax Income -$1.220M -$8.020M -$1.870M
YoY Change -45.78% -19.88% -22.73%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.225M -$8.019M -$1.870M
YoY Change -45.66% -19.87% -22.73%
Net Earnings / Revenue -91.97% -151.91% -123.03%
Basic Earnings Per Share
Diluted Earnings Per Share -$61.00M -$802.0M -$187.0M
COMMON SHARES
Basic Shares Outstanding 5.946M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q1 2013 2012 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.580M $9.200M $8.700M
YoY Change 10.01% 5.75% -15.45%
Cash & Equivalents $7.584M $9.200M $8.699M
Short-Term Investments
Other Short-Term Assets $480.0K $420.0K $470.0K
YoY Change 14.29% -10.64% -11.32%
Inventory $665.7K $560.0K $834.5K
Prepaid Expenses
Receivables $530.7K $390.0K $566.5K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $9.256M $10.57M $10.57M
YoY Change 7.26% 0.0% -21.65%
LONG-TERM ASSETS
Property, Plant & Equipment $198.5K $230.0K $293.9K
YoY Change -23.67% -20.69% -39.22%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00 $10.00K
YoY Change -100.0% -95.83%
Total Long-Term Assets $199.3K $230.0K $304.4K
YoY Change -23.33% -25.81% -58.04%
TOTAL ASSETS
Total Short-Term Assets $9.256M $10.57M $10.57M
Total Long-Term Assets $199.3K $230.0K $304.4K
Total Assets $9.456M $10.80M $10.88M
YoY Change 6.36% -0.74% -23.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $578.0K $320.0K $257.4K
YoY Change 151.3% 23.08% -59.1%
Accrued Expenses $791.6K $1.260M $948.8K
YoY Change -49.9% -21.25% -22.36%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $20.00K
YoY Change -100.0% 0.0%
Total Short-Term Liabilities $1.970M $1.650M $2.006M
YoY Change 1.54% -17.91% -33.43%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $1.440M $1.950M $70.00K
YoY Change 2300.0% 2685.71% -30.0%
Total Long-Term Liabilities $1.440M $1.950M $70.00K
YoY Change 2300.0% 2685.71% -41.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.970M $1.650M $2.006M
Total Long-Term Liabilities $1.440M $1.950M $70.00K
Total Liabilities $3.409M $3.600M $2.077M
YoY Change 70.44% 73.08% -33.69%
SHAREHOLDERS EQUITY
Retained Earnings -$147.8M -$138.6M
YoY Change 7.78%
Common Stock $595.00 $214.00
YoY Change -45.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.047M $7.190M $8.800M
YoY Change
Total Liabilities & Shareholders Equity $9.456M $10.80M $10.88M
YoY Change 6.36% -0.74% -23.51%

Cashflow Statement

Concept 2014 Q1 2013 2012 Q4
OPERATING ACTIVITIES
Net Income -$1.225M -$8.019M -$1.870M
YoY Change -45.66% -19.87% -22.73%
Depreciation, Depletion And Amortization $30.00K $150.7K $40.00K
YoY Change -25.0% -37.01% -50.0%
Cash From Operating Activities -$1.608M -$6.555M -$2.210M
YoY Change -10.76% -28.56% 53.47%
INVESTING ACTIVITIES
Capital Expenditures $4.115K $86.08K -$30.00K
YoY Change -32.14% -19.9% -400.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$4.115K -$86.08K -$30.00K
YoY Change -32.14% -170.54% -400.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $0.00 $7.137M 0.000
YoY Change -100.0% -4.36% -100.0%
NET CHANGE
Cash From Operating Activities -$1.608M -$6.555M -2.210M
Cash From Investing Activities -$4.115K -$86.08K -30.00K
Cash From Financing Activities $0.00 $7.137M 0.000
Net Change In Cash -$1.612M $496.3K -2.240M
YoY Change -11.09% -131.19% 57.75%
FREE CASH FLOW
Cash From Operating Activities -$1.608M -$6.555M -$2.210M
Capital Expenditures $4.115K $86.08K -$30.00K
Free Cash Flow -$1.612M -$6.641M -$2.180M
YoY Change -10.83% -28.46% 50.34%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2012Q4 nuro Common Stock Warrants
CommonStockWarrants
0 USD
CY2012Q4 us-gaap Liabilities
Liabilities
2077025 USD
CY2013Q4 us-gaap Inventory Net
InventoryNet
563036 USD
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
390922 USD
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2005606 USD
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
229313 USD
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
386004 USD
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
870196 USD
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
322896 USD
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
416816 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
10566527 USD
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
68812 USD
CY2013Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
923 USD
CY2013Q4 us-gaap Assets
Assets
10796763 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9195753 USD
CY2013Q4 us-gaap Liabilities
Liabilities
3601788 USD
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q4 nuro Common Stock Warrants
CommonStockWarrants
1938603 USD
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
595 USD
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
153806460 USD
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-146612080 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
7194975 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10796763 USD
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1647908 USD
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
15277 USD
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2239511 shares
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013 us-gaap Use Of Estimates
UseOfEstimates
<div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <h3 style="TEXT-ALIGN: left; PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 24px; PADDING-RIGHT: 0pt; FONT: bold italic 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 5pt"> Use of Estimates and Assumptions</h3> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-TRANSFORM: none; PADDING-BOTTOM: 3pt; PADDING-TOP: 3pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-LEFT: 4px; MARGIN: 0pt; PADDING-RIGHT: 0pt; TEXT-INDENT: 20px" align="left">The preparation of financial statements in conformity with United States generally accepted accounting principles requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during reporting periods. Actual results could differ from those estimates.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-TRANSFORM: none; PADDING-BOTTOM: 3pt; PADDING-TOP: 3pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-LEFT: 4px; MARGIN: 0pt; PADDING-RIGHT: 0pt; TEXT-INDENT: 20px" align="left">The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances and regularly assesses these estimates, but actual results could differ materially from these estimates. Effects of changes in estimates are recorded in the period in which they occur.</div> </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8699478 USD
CY2012Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
566451 USD
CY2012Q4 us-gaap Inventory Net
InventoryNet
834526 USD
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
472611 USD
CY2012Q4 us-gaap Assets Current
AssetsCurrent
10573066 USD
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
293897 USD
CY2012Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
10484 USD
CY2012Q4 us-gaap Assets
Assets
10877447 USD
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
257361 USD
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
647288 USD
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
948843 USD
CY2011 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
334549 shares
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
134185 USD
CY2012Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
17929 USD
CY2013Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
0 USD
CY2012Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
71419 USD
CY2012 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0 USD
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
214 USD
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
147393151 USD
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-138592943 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
8800422 USD
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10877447 USD
CY2013Q2 us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
248147 shares
CY2013Q2 us-gaap Share Price
SharePrice
2.095
CY2013Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
2.00
CY2013Q2 nuro Class Of Warrant Or Right Exercisable Period
ClassOfWarrantOrRightExercisablePeriod
P5Y
CY2013Q2 nuro Gross Proceeds From Issuance Or Sale Of Equity
GrossProceedsFromIssuanceOrSaleOfEquity
5000000 USD
CY2013Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
4500000 USD
CY2013Q2 nuro Common Stock Warrants Issued
CommonStockWarrantsIssued
2365934 shares
CY2012 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
827244 shares
CY2011 us-gaap Net Income Loss
NetIncomeLoss
-9981105 USD
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-10007553 USD
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-8019137 USD
CY2011 nuro Deemed Dividends Attributable To Preferred Stock In Connection With Embedded Features
DeemedDividendsAttributableToPreferredStockInConnectionWithEmbeddedFeatures
0 USD
CY2012 nuro Deemed Dividends Attributable To Preferred Stock In Connection With Embedded Features
DeemedDividendsAttributableToPreferredStockInConnectionWithEmbeddedFeatures
0 USD
CY2013 nuro Deemed Dividends Attributable To Preferred Stock In Connection With Embedded Features
DeemedDividendsAttributableToPreferredStockInConnectionWithEmbeddedFeatures
-766872 USD
CY2011 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9981105 USD
CY2012 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10007553 USD
CY2013 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8786009 USD
CY2011 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-15.53
CY2012 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.22
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.07
CY2011 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
642513 shares
CY2012 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1918723 shares
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2862094 shares
CY2012Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
187567 USD
CY2013Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
205320 USD
CY2012Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
646959 USD
CY2013Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
3926600 USD
CY2012Q1 nuro Unit Issued During Period Price Per Unit New Issues
UnitIssuedDuringPeriodPricePerUnitNewIssues
6.00
CY2013Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
357716 USD
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2140871 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5945581 shares
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2140871 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5945581 shares
CY2012Q4 nuro Technology Fees
TechnologyFees
450000 USD
CY2013Q4 nuro Technology Fees
TechnologyFees
450000 USD
CY2012Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
248759 USD
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
263642 USD
CY2012Q4 us-gaap Significant Supply Commitment Remaining Minimum Amount Committed
SignificantSupplyCommitmentRemainingMinimumAmountCommitted
105132 USD
CY2013Q4 us-gaap Significant Supply Commitment Remaining Minimum Amount Committed
SignificantSupplyCommitmentRemainingMinimumAmountCommitted
0 USD
CY2012Q4 nuro Clinical Study Obligations
ClinicalStudyObligations
24490 USD
CY2013Q4 nuro Clinical Study Obligations
ClinicalStudyObligations
51424 USD
CY2012Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
62385 USD
CY2013Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
32688 USD
CY2012Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
58077 USD
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
72442 USD
CY2013Q2 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2015-03-31
CY2013 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
52917 USD
CY2013Q4 us-gaap Share Price
SharePrice
2.92
CY2013Q4 us-gaap Fair Value Assumptions Exercise Price
FairValueAssumptionsExercisePrice
2.00
CY2013 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0171 pure
CY2013 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.6760 pure
CY2012Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
519242 USD
CY2012Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
519242 USD
CY2013Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
3926600 USD
CY2013Q4 nuro Common Stock Warrants Fair Value Disclosure
CommonStockWarrantsFairValueDisclosure
1938603 USD
CY2013Q4 us-gaap Liabilities Fair Value Disclosure Recurring
LiabilitiesFairValueDisclosureRecurring
1938603 USD
CY2013Q4 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
2500000 USD
CY2013 us-gaap Line Of Credit Facility Expiration Date1
LineOfCreditFacilityExpirationDate1
2015-01-15
CY2013Q4 nuro Restricted Cash Collateral Letters Of Credit
RestrictedCashCollateralLettersOfCredit
225000 USD
CY2013Q4 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
2275000 USD
CY2012Q1 nuro Public Offering Units
PublicOfferingUnits
1421735 shares
CY2012Q1 nuro Public Offering Of Units Description
PublicOfferingOfUnitsDescription
Each Unit consists of one share of the Companys common stock and one warrant to purchase one half of a share of the Companys common stock.
CY2012Q1 nuro Stock Issued During Period Shares Public Offering
StockIssuedDuringPeriodSharesPublicOffering
1421735 shares
CY2012Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
7400000 USD
CY2012Q1 nuro Class Of Warrant Or Right Exercisable Period
ClassOfWarrantOrRightExercisablePeriod
P5Y
CY2012Q1 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
2400000 USD
CY2012Q1 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.735 pure
CY2012Q1 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0085 pure
CY2012Q1 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P5Y
CY2013 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P5Y
CY2011 us-gaap Revenues
Revenues
10396775 USD
CY2012 us-gaap Revenues
Revenues
7575289 USD
CY2013 us-gaap Revenues
Revenues
5278806 USD
CY2011 us-gaap Cost Of Revenue
CostOfRevenue
4722069 USD
CY2012 us-gaap Cost Of Revenue
CostOfRevenue
3588806 USD
CY2013 us-gaap Cost Of Revenue
CostOfRevenue
2194259 USD
CY2011 us-gaap Gross Profit
GrossProfit
5674706 USD
CY2012 us-gaap Gross Profit
GrossProfit
3986483 USD
CY2013 us-gaap Gross Profit
GrossProfit
3084547 USD
CY2011 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3877526 USD
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3545790 USD
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3438218 USD
CY2011 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6688591 USD
CY2012 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5727482 USD
CY2013 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2779695 USD
CY2011 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5111616 USD
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4735238 USD
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4225474 USD
CY2011 us-gaap Operating Expenses
OperatingExpenses
15677733 USD
CY2012 us-gaap Operating Expenses
OperatingExpenses
14008510 USD
CY2013 us-gaap Operating Expenses
OperatingExpenses
10443387 USD
CY2011 us-gaap Operating Income Loss
OperatingIncomeLoss
-10003027 USD
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-10022027 USD
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-7358840 USD
CY2011 us-gaap Interest And Other Income
InterestAndOtherIncome
21922 USD
CY2012 us-gaap Interest And Other Income
InterestAndOtherIncome
14474 USD
CY2013 us-gaap Interest And Other Income
InterestAndOtherIncome
5666 USD
CY2011 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
0 USD
CY2012 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
0 USD
CY2013 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
376306 USD
CY2011 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
CY2012 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
CY2013 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
289657 USD
CY2011 us-gaap Depreciation And Amortization
DepreciationAndAmortization
376932 USD
CY2012 us-gaap Depreciation And Amortization
DepreciationAndAmortization
297097 USD
CY2013 us-gaap Depreciation And Amortization
DepreciationAndAmortization
150663 USD
CY2011 us-gaap Share Based Compensation
ShareBasedCompensation
837040 USD
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
319368 USD
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
245843 USD
CY2011 us-gaap Inventory Write Down
InventoryWriteDown
98556 USD
CY2012 us-gaap Inventory Write Down
InventoryWriteDown
234848 USD
CY2013 us-gaap Inventory Write Down
InventoryWriteDown
151558 USD
CY2011 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0 USD
CY2013 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-376306 USD
CY2011 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-682846 USD
CY2012 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-343267 USD
CY2013Q4 nuro Preferred Stock Stated Value Per Share
PreferredStockStatedValuePerShare
1000
CY2013Q4 us-gaap Preferred Stock Discount On Shares
PreferredStockDiscountOnShares
766900 USD
CY2013Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2365934 shares
CY2013 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-290000 USD
CY2013 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-175529 USD
CY2011 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-550549 USD
CY2012 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-694327 USD
CY2013 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-119932 USD
CY2011 nuro Stock Issuance Settle Incentive Compensation Obligation
StockIssuanceSettleIncentiveCompensationObligation
0 USD
CY2012 nuro Stock Issuance Settle Incentive Compensation Obligation
StockIssuanceSettleIncentiveCompensationObligation
0 USD
CY2013 nuro Stock Issuance Settle Incentive Compensation Obligation
StockIssuanceSettleIncentiveCompensationObligation
-285295 USD
CY2011 nuro Supplemental Warrant Issued To Placement Agent And Investors In Private Placement
SupplementalWarrantIssuedToPlacementAgentAndInvestorsInPrivatePlacement
0 USD
CY2013 dei Trading Symbol
TradingSymbol
NURO
CY2013 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2013 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
496275 USD
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16986809 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10290446 USD
CY2013 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2013 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2013Q2 dei Entity Public Float
EntityPublicFloat
4743950 USD
CY2012Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
151616 USD
CY2013Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
35895 USD
CY2011 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-110400 USD
CY2012 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
76880 USD
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-52748 USD
CY2011 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
370060 USD
CY2012 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-371854 USD
CY2013 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
65535 USD
CY2011 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
240433 USD
CY2012 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-530141 USD
CY2013 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-54635 USD
CY2011 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6778398 USD
CY2012 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9175567 USD
CY2013 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6554908 USD
CY2011 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
110987 USD
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
107465 USD
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
86079 USD
CY2011 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-178500 USD
CY2012 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-229500 USD
CY2013 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
0 USD
CY2011 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
67513 USD
CY2012 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
122035 USD
CY2013 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-86079 USD
CY2011 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
33614 USD
CY2012 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
7482884 USD
CY2013 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
7155191 USD
CY2011 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
19092 USD
CY2012 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
20320 USD
CY2013 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
17929 USD
CY2011 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14522 USD
CY2012 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7462564 USD
CY2013 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7137262 USD
CY2011 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-6696363 USD
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1590968 USD
CY2012 nuro Supplemental Warrant Issued To Placement Agent And Investors In Private Placement
SupplementalWarrantIssuedToPlacementAgentAndInvestorsInPrivatePlacement
0 USD
CY2013 nuro Supplemental Warrant Issued To Placement Agent And Investors In Private Placement
SupplementalWarrantIssuedToPlacementAgentAndInvestorsInPrivatePlacement
4011205 USD
CY2011 us-gaap Stock Issued1
StockIssued1
0 USD
CY2012 us-gaap Stock Issued1
StockIssued1
127885 USD
CY2013 us-gaap Stock Issued1
StockIssued1
0 USD
CY2013 dei Document Type
DocumentType
10-K
CY2013 dei Amendment Flag
AmendmentFlag
false
CY2013 dei Document Period End Date
DocumentPeriodEndDate
2013-12-31
CY2013 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2013 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2014Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
5945581 shares
CY2013 dei Entity Registrant Name
EntityRegistrantName
NeuroMetrix, Inc.
CY2013 dei Entity Central Index Key
EntityCentralIndexKey
0001289850
CY2011 us-gaap Depreciation
Depreciation
359432 USD
CY2012 us-gaap Depreciation
Depreciation
239168 USD
CY2013 us-gaap Depreciation
Depreciation
150663 USD
CY2013Q2 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
477.327 shares
CY2013Q2 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2600000 USD
CY2012Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4510847 USD
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3180495 USD
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4216950 USD
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2951182 USD
CY2012 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
CY2013 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
CY2012Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
30514469 USD
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
32253602 USD
CY2012Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1547374 USD
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1735265 USD
CY2012Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
643952 USD
CY2011Q1 us-gaap Restructuring And Related Cost Number Of Positions Eliminated
RestructuringAndRelatedCostNumberOfPositionsEliminated
25 pure
CY2011Q1 us-gaap Restructuring And Related Cost Expected Cost
RestructuringAndRelatedCostExpectedCost
2200000 USD
CY2010 us-gaap Restructuring Charges
RestructuringCharges
2000000 USD
CY2010 us-gaap Severance Costs1
SeveranceCosts1
200000 USD
CY2011 us-gaap Severance Costs1
SeveranceCosts1
200000 USD
CY2010 nuro Business Restructuring Charged To Inventory
BusinessRestructuringChargedToInventory
1800000 USD
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
493075 USD
CY2012Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
593131 USD
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
565077 USD
CY2012Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1048541 USD
CY2013Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1061212 USD
CY2012Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
34347467 USD
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
36108231 USD
CY2012Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2013Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2012 nuro Stock Issued During Period Values Redemption Of Warrants
StockIssuedDuringPeriodValuesRedemptionOfWarrants
0 USD
CY2012Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
18629 USD
CY2013Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
4719 USD
CY2012 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.008 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.034 pure
CY2011 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.005 pure
CY2012 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.017 pure
CY2011 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.360 pure
CY2012 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.367 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.371 pure
CY2011 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
CY2013Q4 nuro Income Tax Expense Benefit Attributable To Net Operating Loss Carry Forward
IncomeTaxExpenseBenefitAttributableToNetOperatingLossCarryForward
3900000 USD
CY2013Q4 nuro Income Tax Expense Benefit Attributable To Tax Credit Carry Forwards
IncomeTaxExpenseBenefitAttributableToTaxCreditCarryForwards
71000 USD
CY2011 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2012 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2013 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2011 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0 USD
CY2012 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0 USD
CY2013 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0 USD
CY2011 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2012 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2011 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
-0.340 pure
CY2012 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
-0.340 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
-0.340 pure
CY2011 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.034 pure
CY2012 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.035 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.048 pure
CY2011 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.019 pure
CY2012Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
34347467 USD
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
36108231 USD
CY2013Q4 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
2.095
CY2013Q4 nuro Class Of Class Stock Warrants Or Rights Exercised
ClassOfClassStockWarrantsOrRightsExercised
1300000 shares
CY2012Q4 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
18446 USD
CY2012Q4 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
18446 USD
CY2012Q4 us-gaap Capital Leases Future Minimum Payments Interest Included In Payments
CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
517 USD
CY2012Q4 us-gaap Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments
CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments
17929 USD
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
635004 USD
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
158751 USD
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
793755 USD
CY2009Q1 nuro Business Acquisition Purchase Price Allocation Amortizable Intangible Assets1
BusinessAcquisitionPurchasePriceAllocationAmortizableIntangibleAssets1
350000 USD
CY2009Q1 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P5Y
CY2011 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
764754 USD
CY2012 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
709164 USD
CY2013 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
635004 USD
CY2010Q4 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
60410 USD
CY2011Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
17500 USD
CY2012 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0 USD
CY2013 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0 USD
CY2013Q4 us-gaap Purchase Obligation
PurchaseObligation
147806 USD
CY2011Q2 us-gaap Asset Impairment Charges
AssetImpairmentCharges
192500 USD
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
19.89
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
81.00
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.20
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
14.20
CY2010Q4 us-gaap Stockholders Equity
StockholdersEquity
20198972 USD
CY2011 us-gaap Asset Impairment Charges
AssetImpairmentCharges
192500 USD
CY2012 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
CY2013 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
CY2011 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
837040 USD
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
319368 USD
CY2013 nuro Reclassification Of Warrant Liability To Additional Paid In Capital Upon Exercise Of Warrants
ReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalUponExerciseOfWarrants
2362259 USD
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7 pure
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7 pure
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
85.01
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y7D
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y11M16D
CY2013 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <h3 style="TEXT-ALIGN: left; PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 24px; PADDING-RIGHT: 0pt; FONT: bold italic 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 5pt"> Concentrations of Credit Risk</h3> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-TRANSFORM: none; PADDING-BOTTOM: 3pt; PADDING-TOP: 3pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-LEFT: 4px; MARGIN: 0pt; PADDING-RIGHT: 0pt; TEXT-INDENT: 20px" align="left">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents in bank deposit accounts and trade receivables. The Company invests its funds in highly rated institutions and limits its investment in any individual account so that they do not exceed FDIC limits. The Company has not experienced significant losses related to cash and cash equivalents and does not believe it is exposed to any significant credit risks relating to its cash and cash equivalents.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-TRANSFORM: none; PADDING-BOTTOM: 3pt; PADDING-TOP: 3pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-LEFT: 4px; MARGIN: 0pt; PADDING-RIGHT: 0pt; TEXT-INDENT: 20px" align="left">At December 31, 2013, one customer accounted for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 14</font>% of accounts receivable and a second customer accounted for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 12</font>% of accounts receivable. For the years ended December 31, 2013, 2012, and 2011, no single customer accounted for more than 10% of revenue.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-TRANSFORM: none; PADDING-BOTTOM: 3pt; PADDING-TOP: 3pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-LEFT: 4px; MARGIN: 0pt; PADDING-RIGHT: 0pt; TEXT-INDENT: 20px" align="left">The Company relies on in-house assembly and three third-party manufacturers to manufacture the major portion of its current products and product components. The disruption or termination of the supply of these products or a significant increase in the cost of these products from these sources could have an adverse effect on the Company&#8217;s business, financial position, and results of operations.</div> </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2013 nuro Stock Issued During Period Value Securities Purchase Agreement
StockIssuedDuringPeriodValueSecuritiesPurchaseAgreement
876786 USD
CY2013 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 USD
CY2013 nuro Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
2617222 USD
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
11088521 USD
CY2012 nuro Stock Issued During Period Value Public Offering
StockIssuedDuringPeriodValuePublicOffering
7377048 USD
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y7M2D
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
278018 USD
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
306925 USD
CY2013Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 USD
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
245843 USD
CY2011 nuro Warrants Issued In Public Offering
WarrantsIssuedInPublicOffering
0 USD
CY2012 nuro Warrants Issued In Public Offering
WarrantsIssuedInPublicOffering
2373267 USD
CY2013 nuro Warrants Issued In Public Offering
WarrantsIssuedInPublicOffering
0 USD
CY2011 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
33614 USD
CY2012 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
23038 USD
CY2013 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
26285 USD
CY2011 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
0 USD
CY2012 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
0 USD
CY2013 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2362259 USD
CY2011 nuro Reclassification Of Warrant Liability To Additional Paid In Capital Upon Exercise Of Warrants
ReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalUponExerciseOfWarrants
0 USD
CY2012 nuro Reclassification Of Warrant Liability To Additional Paid In Capital Upon Exercise Of Warrants
ReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalUponExerciseOfWarrants
0 USD
CY2011 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
426000 USD
CY2012 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
242000 USD
CY2013 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
151000 USD
CY2011 nuro Sales Revenue Goods Net Percentage From Foreigen Country
SalesRevenueGoodsNetPercentageFromForeigenCountry
0.06 pure
CY2012 nuro Sales Revenue Goods Net Percentage From Foreigen Country
SalesRevenueGoodsNetPercentageFromForeigenCountry
0.07 pure
CY2013 nuro Sales Revenue Goods Net Percentage From Foreigen Country
SalesRevenueGoodsNetPercentageFromForeigenCountry
0.16 pure
CY2013Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2669202 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
38272 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
2000 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
3375 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
17476 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
5.25
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.90
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
5.66
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
4.20
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
4.62
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
19421 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
51550 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
265000 shares
CY2013 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
5945 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
459 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
310146 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
285291 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
41620 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
73.38
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.76
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
300000 shares
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.34
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.67
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.02
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
0
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
0
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
0
CY2013Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
247468 USD
CY2013Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
286022 shares
CY2013Q4 nuro Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Price Per Shares
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAveragePricePerShares
0.87
CY2013 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P4M24D
CY2011 us-gaap Stock Issued During Period Shares Restricted Stock Award Gross
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
3630 shares
CY2012 us-gaap Stock Issued During Period Shares Restricted Stock Award Gross
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
37167 shares
CY2013 us-gaap Stock Issued During Period Shares Restricted Stock Award Gross
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
2000 shares
CY2012 nuro Number Of Shares Authorized To With Holding In Lieu Of Paying With Holding Taxes
NumberOfSharesAuthorizedToWithHoldingInLieuOfPayingWithHoldingTaxes
721 shares
CY2013 nuro Number Of Shares Authorized To With Holding In Lieu Of Paying With Holding Taxes
NumberOfSharesAuthorizedToWithHoldingInLieuOfPayingWithHoldingTaxes
4214 shares
CY2011 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
34000 USD
CY2012 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
23000 USD
CY2013 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
26000 USD
CY2011 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
837000 USD
CY2012 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
319000 USD
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
246000 USD
CY2012Q1 us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
23127 shares
CY2012Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
781955 shares
CY2013Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2365934 shares
CY2013Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
119370 shares
CY2013Q1 us-gaap Accrued Bonuses Current And Noncurrent
AccruedBonusesCurrentAndNoncurrent
285300 USD
CY2013Q1 nuro Closing Price Of Shares
ClosingPriceOfShares
2.39
CY2012Q1 nuro Exercise Price Of Warrants
ExercisePriceOfWarrants
6.90
CY2013 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2013 nuro Maximum Term Of Grant Of Common Stock
MaximumTermOfGrantOfCommonStock
P5Y
CY2013Q2 nuro Class Of Warrants Or Right Exercise Period
ClassOfWarrantsOrRightExercisePeriod
five year warrants
CY2012Q1 nuro Per Unit Of Common Stock Description
PerUnitOfCommonStockDescription
one share of the Companys common stock and one warrant to purchase one half of a share of the Companys common stock
CY2011 nuro Increase Decrease In Deferred Revenue Deferred Costs And Other Liabilities
IncreaseDecreaseInDeferredRevenueDeferredCostsAndOtherLiabilities
-256609 USD
CY2012 nuro Increase Decrease In Deferred Revenue Deferred Costs And Other Liabilities
IncreaseDecreaseInDeferredRevenueDeferredCostsAndOtherLiabilities
-78046 USD
CY2013 nuro Increase Decrease In Deferred Revenue Deferred Costs And Other Liabilities
IncreaseDecreaseInDeferredRevenueDeferredCostsAndOtherLiabilities
-108907 USD
CY2013 nuro Line Of Credit Facility Maximum Borrowing Capacity In Case Of Not Compliance With Agreement
LineOfCreditFacilityMaximumBorrowingCapacityInCaseOfNotComplianceWithAgreement
750000 USD
CY2013 nuro Stock Issued During Period Value To Settle Incentive Compensation Obligations
StockIssuedDuringPeriodValueToSettleIncentiveCompensationObligations
285295 USD

Files In Submission

Name View Source Status
0001144204-14-011172-index-headers.html Edgar Link pending
0001144204-14-011172-index.html Edgar Link pending
0001144204-14-011172.txt Edgar Link pending
0001144204-14-011172-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
line.gif Edgar Link pending
nuro-20131231.xml Edgar Link completed
nuro-20131231.xsd Edgar Link pending
nuro-20131231_cal.xml Edgar Link unprocessable
nuro-20131231_def.xml Edgar Link unprocessable
nuro-20131231_lab.xml Edgar Link unprocessable
nuro-20131231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
spacer.gif Edgar Link pending
v365797_10k.htm Edgar Link pending
v365797_ex23-1.htm Edgar Link pending
v365797_ex31-1.htm Edgar Link pending
v365797_ex31-2.htm Edgar Link pending
v365797_ex32.htm Edgar Link pending